{"id":550067,"date":"2021-06-28T21:26:01","date_gmt":"2021-06-28T21:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550067"},"modified":"2021-06-28T21:26:01","modified_gmt":"2021-06-28T21:26:01","slug":"malaria-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-glaxosmithkline-sanaria-tarsus-pharmaceuticals-novartis-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/malaria-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-glaxosmithkline-sanaria-tarsus-pharmaceuticals-novartis-and-many-others_550067.html","title":{"rendered":"Malaria Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GlaxoSmithKline, Sanaria, Tarsus Pharmaceuticals, Novartis and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1624857002.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Malaria Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GlaxoSmithKline, Sanaria, Tarsus Pharmaceuticals, Novartis and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1624857002.jpeg\" alt=\"Malaria Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GlaxoSmithKline, Sanaria, Tarsus Pharmaceuticals, Novartis and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Malaria Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Malaria<\/a><\/strong> is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called &#8220;malaria vectors.&#8221; There are 5 parasite species that cause malaria in humans, and 2 of these species &ndash; P. falciparum and P. vivax &ndash; pose the greatest threat.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Malaria Pipeline<\/a> Insight, 2021&rdquo;&nbsp;<\/strong>report provides comprehensive insights about&nbsp;<strong>20+ companies and 20+ pipeline drugs<\/strong>&nbsp;in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Malaria Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>GlaxoSmithKline<\/li>\n<li>Sanaria<\/li>\n<li>Tarsus Pharmaceuticals<\/li>\n<li>Novartis<\/li>\n<li>Nobelpharma<\/li>\n<li>Curevac<\/li>\n<li>Novavax<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/malaria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\">https:\/\/www.delveinsight.com\/sample-request\/malaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Malaria Report covers around 20+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Malaria Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>R21<\/li>\n<li>KAF156<\/li>\n<li>NPC-19<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tuberculosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/Malaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Malaria Treatment Scenario and Malaria Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Malaria drugs?<\/li>\n<li>How many Malaria drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malaria?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Malaria and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Malaria: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Malaria&ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Malaria Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">R21: GlaxoSmithKline<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">KAF156: Novartis<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">NPC-19: Nobelpharma<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical and Discovery Stage Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Research Programme: Malaria: Carna Biosciences<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Malaria Key Companies<\/p>\n<p style=\"text-align: justify;\">Malaria Key Products<\/p>\n<p style=\"text-align: justify;\">Malaria- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Malaria- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Malaria- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Malaria Analyst Views<\/p>\n<p style=\"text-align: justify;\">Malaria Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/malaria-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=malaria-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-glaxosmithkline-sanaria-tarsus-pharmaceuticals-novartis-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/malaria-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=malaria-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-glaxosmithkline-sanaria-tarsus-pharmaceuticals-novartis-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Malaria Pipeline Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/malaria-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-glaxosmithkline-sanaria-tarsus-pharmaceuticals-novartis-and-many-others_550067.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-550067","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550067"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}